Clinical Handbook of Psychotropic Drugs for Children and Adolescents

The Clinical Handbook of Psychotropic Drugs for Children and Adolescents has become a standard reference and working tool for psychiatrists, pediatricians, psychologists, physicians, pharmacists, nurses, and other mental health professionals. • • Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options • • Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, nursing implications, and much more – all you need to know for each class of drug • • Potential interactions and side effects summarized in comparison charts • • With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek • • Clearly written patient and caregiver information sheets for download as printable PDF files This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs. New in this edition: • • Drugs for ADHD thoroughly revised and updated • • Antipsychotics with many changes and additions, including fully revised lab tests/monitoring • • Antidepressants fully revised, including new sections on irreversible MAO-B inhibitor and serotonin modulator and stimulator (SMS), revised frequency of adverse effects table and switching strategies recommendations • • Hypnotics completely revised • • Mood stabilizers fully revised and a new toxicity comparison table added • • Drugs of abuse and treatment of substance use disorder comprehensively revised • • New unapproved treatments with significant updates, including: anti-inflammatories and NMDA agents in anxiety/OCD, cannabis use, and irritability of autism • • New agents include: TGAs N-arylpiperazine (brexpiprazole) and phenylpiperazine (cariprazine), hypnotics orexin receptor antagonist (hypnotic suvorexant) and selective melatonin agonist (tasimelteon), antidepressant bisarylsulfanyl amine (vortioxetine) • • New formulations and trade names include: Adasuve, Alprazolam Intensol, Aptensio XR, Aristada, Belbuca, Belsomra, Brintellix, Bunavail, Cotempla XR-ODT, Dyanavel XR, Eldepryl, EMSAM, Evekeo, Hemangeol, Hetlioz, Innopran XL, Invega Trinza, Khedezla, Metadol-D, Mydayis, NyQuil, Quillichew ER, Quillivant XR, Rexulti, Som-Pam, Tegretol (liquid), Trintellix, Versacolz, Vraylar, Vyvanse, Zelapar, Zenzedi

Dean Elbe; BScPharm, PharmD, BCPP; Children’s & Women’s Health Centre of British Columbia, Vancouver, BC, Canada.Tyler R. Black; BSc, MD, FRCPC; British Columbia Children's Hospital, Vancouver, BC, Canada.Ian R. McGrane; PharmD, BCPS, BCPP; Skaggs School of Pharmacy, University of Montana, Missoula, MT, USA.Ric M. Procyshyn; BScPharm, MSc, PharmD, PhD; British Columbia Mental Health & Addictions Research Institute, Vancouver, BC, Canada.